MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$783,300K
Net Income
$333,000K
Net Profit Margin
42.51%
EPS
$7.27
Unit: Thousand (K) dollars
Revenue Breakdown
Tyvaso DPI
Remodulin
Nebulized Tyvaso
Others
Revenue Breakdown
US
Non Us
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
783,300
781,500
790,200
799,500
Cost of sales
99,500
133,400
103,400
100,900
Research and development
146,300
138,200
139,500
127,500
Selling, general, and administrative
206,700
184,100
190,600
182,600
Total operating expenses
452,500
455,700
433,500
411,000
Operating income
330,800
325,800
356,700
388,500
Interest income
31,500
41,800
43,200
46,400
Interest expense
2,900
3,000
3,100
3,000
Other income (expense), net
13,300
-46,300
47,200
6,100
Total other income, net
41,900
-7,500
87,300
49,500
Income before income taxes
372,700
318,300
444,000
438,000
Income tax expense
39,700
43,400
79,700
99,300
Net income
333,000
274,900
364,300
338,700
Basic EPS
7.82
6.32
8.394
7.73
Diluted EPS
7.27
5.82
7.686
7.16
Basic Average Shares
42,600,000
43,500,000
43,400,000
43,800,000
Diluted Average Shares
45,800,000
47,200,000
47,400,000
47,300,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
US
$99,400K
(-86.92%↓ Y/Y)
Non Us
$26,900K
(-30.67%↓ Y/Y)
US
$109,700K
(-85.56%↓ Y/Y)
Non Us
$16,300K
(-57.99%↓ Y/Y)
US
$59,000K
(-92.23%↓ Y/Y)
Non Us
$6,200K
(-84.02%↓ Y/Y)
US
$6,500K
(-99.14%↓ Y/Y)
Non Us
$300K
(-99.23%↓ Y/Y)
Tyvaso DPI
$326,600K
Remodulin
$126,300K
(-6.24%↓ Y/Y)
Nebulized Tyvaso
$126,000K
(-18.39%↓ Y/Y)
Orenitram
$125,700K
(1.45%↑ Y/Y)
Unituxin
$65,200K
(11.64%↑ Y/Y)
Product And Service
Other
$6,800K
(23.64%↑ Y/Y)
Adcirca
$6,700K
(3.08%↑ Y/Y)
Total revenues
$783,300K
(-1.92%↓ Y/Y)
Interest income
$31,500K
(-38.60%↓ Y/Y)
Other income
(expense), net
$13,300K
(13400.00%↑ Y/Y)
Operating income
$330,800K
(-9.25%↓ Y/Y)
Total other income,
net
$41,900K
(-4.56%↓ Y/Y)
Total operating
expenses
$452,500K
(4.24%↑ Y/Y)
Interest expense
$2,900K
(-60.27%↓ Y/Y)
Income before income
taxes
$372,700K
(-8.74%↓ Y/Y)
Selling, general, and
administrative
$206,700K
(-2.73%↓ Y/Y)
Research and development
$146,300K
(9.18%↑ Y/Y)
Cost of sales
$99,500K
(13.58%↑ Y/Y)
Net income
$333,000K
(7.59%↑ Y/Y)
Income tax expense
$39,700K
(-59.86%↓ Y/Y)
Buy us a coffee
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)